Back to Hematology
Hematologyv2018Evidence-Based

Mayo Alliance Prognostic System (MAPS) Score

Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.

Clinical Input Parameters

years
Range: 18 — 100 years
×10⁹/L
Range: 10 — 1000 ×10⁹/L
Clinical Assessment
Awaiting Parameters
maps score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Mayo Alliance Prognostic System (MAPS) Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MAPS Score = SM Type points + Age points + Platelet points + ALP points + Adverse mutations points. Maximum score 6 points (Advanced SM: 2 + Age >60: 1 + Platelets <150: 1 + Elevated ALP: 1 + Adverse mutations: 1)

Clinical Pearls & Practice Notes

  • Developed from analysis of 580 patients at Mayo Clinic between 1968-2015
  • Two models available: clinical only and hybrid clinical-molecular model
  • Risk factors are directly and proportionally correlated with survival
  • Score of 0-1 associated with median survival not reached and 99% 5-year survival
  • Advanced SM includes aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia
  • Adverse mutations include ASXL1, RUNX1, and NRAS variants
  • Serum alkaline phosphatase elevation may indicate liver or bone involvement
  • Thrombocytopenia threshold of 150 ×10⁹/L based on WHO criteria
  • Age >60 years represents decreased physiologic reserve and worse outcomes
  • Model validated in independent cohorts with excellent discrimination
  • Should be used in conjunction with WHO classification and clinical assessment
  • Molecular testing enhances prognostic accuracy when available
  • Regular reassessment recommended as disease status may change over time

Evidence & Literature Citations

  1. Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Koschmann J, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018 Nov 27;2(21):2964-2975. doi: 10.1182/bloodadvances.2018024768.
  2. Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436.
  3. Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JN, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019 Nov;6(11):e638-e649. doi: 10.1016/S2352-3026(19)30166-8.
  4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544.

Score Interpretation Ranges

Low Risk0 – 2 pts

Excellent prognosis

Intermediate Risk3 – 4 pts

Intermediate prognosis

High Risk5 – 6 pts

Poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.